AbbVie’s $63 billion acquisition of Allergan was motivated in large part by the Illinois-based company’s belief in the blockbuster wrinkle treatment Botox—and its growth prospects.

But just as the deal became final in May of last year, the coronavirus pandemic tossed a monkey wrench into the equation. After all, who worries about crow’s feet when a deadly virus is on the loose?

Read the full article at